Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

Company Performance - Abbott Laboratories reported fourth-quarter sales of $10.97 billion, which is a 7.2% increase year over year, but it missed the consensus estimate of $11.01 billion [2] - Adjusted diluted earnings per share for Abbott were $1.34, aligning with analyst estimates and management's guidance of $1.31-$1.37, up from $1.19 a year ago [2] - For full-year 2025, Abbott projects adjusted EPS of $5.05-$5.25, compared to a consensus of $5.16, with organic sales growth expected at 7.5%-8.5% and an adjusted operating margin of 23.5%-24.0% [3] Market Movements - Blackboxstocks Inc. shares surged 101% to $3.39 following a $250K securities purchase agreement and potential merger anticipation [9] - Absci Corporation's shares increased by 26% to $4.0450 after Needham initiated coverage with a Buy rating and a $9 price target [9] - ImmunoPrecise Antibodies Ltd. shares rose 30% to $0.6396 after announcing the development of a new class of GLP-1 therapies [9] - Agilysys, Inc. shares fell 21% to $100.00 due to worse-than-expected third-quarter sales results and FY25 revenue guidance below estimates [9] - Hepion Pharmaceuticals, Inc. shares plummeted 61% to $0.1265 after announcing a $9 million public offering [9] - Lisata Therapeutics, Inc. shares dropped 30% to $2.72 following preliminary cohort data from its Phase 2 Ascend trial [9]